Join Our Team


We are always looking for passionate and dedicated people to join our team. Discover today where you and your talents may fit in the Gunning Group.

Support Our Research


We work on the development of new drugs to battle aggressive forms of cancers, including those of blood, brain and breast. You can accelerate our research programs and make a difference.

Featured Video


What's Happening

107. Sensitive detection of Broad-Spectrum Bacteria with small fluorescent excimer chemosensors. Cabral A. D., Rafiei N., de Araujo E. D., Radu T. B., Toutah K., Milstein J., Kraskouskaya D., Gunning P.T., ACS Sensors 2020.


106. Development of conformationally constrained L-shaped scaffolds for selective HDAC8 targeting. Hassan M.M., Ganda G., Nawar N., Israelian J., Manaswiyoungkul P., Raouf Y.S., Armstrong D., Sedighi A., Olasunkanmi O.O., Erdogan F., Cabral A.D., Angeles F., Altintas R., de Araujo E.D., Gunning P.T. (2020) Journal of Medicinal Chemistry.


105. Targeting STAT3 and STAT5 in Cancer. de Araujo E.D., Keserű G.M., Gunning P.T., Moriggl R. Cancers 2020.

104. A Novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukemia. Gawel J. M., Shouksmith A. E., Raouf Y. S., Nawar N., Toutah K., Bukhari S., Manaswiyoungkul P., Olaoye O. O., Israelian J., Radu T. B., Cabral A. D., Sina D., Sedighi A., de Araujo E. D., Gunning P.T. “PTG-0861: (2020) European Journal of Medicinal Chemistry 201:112411

103. STAT5B is expressed in CD34+/CD38- stem cells and serves as a potential molecular target in Ph-negative myeloproliferative neoplasms. Hadzijusufovic E., Keller A., Berger D., Greiner G., Wingelhofer B., Witzeneder N., Ivanov D., Pecnard E., Nivarthi H., Schur F.K.M., Filik Y., Kornauth C., Neubauer H.A., Mullauer L., Tin G., Park J., de Araujo E.D., Gunning P.T., Hoermann G., Gouilleux F., Kralovics R., Moriggl R., Valent P. (2020) Cancers. Accepted IF = 6.102


102. Advances in Covalent Kinase Inhibitors. Abdeldayem, A., Raouf, Y. S., Constantinescu, S., Moriggl, R., Gunning, P. T. ChemSocRev. 2020 Accepted CS-REV-10-2019-000720 IF = 40.443


101. The Development and Optimization of STAT5B High-Throughput Fluorescence Polarization Assay for DNA-Binding Domain-Targeting Inhibitors. Manaswiyoungkul P., Erdogan F., Olaoye O. O., de Araujo E. D., Gunning P. T. J. Pharm Biomed Anal 2020, In press IF = 3.169


100. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. Shouksmith A. E., Gawel J. M., Nawar N., Sina D., Raouf Y. S., Bukhari S., He L., Johns A. E., Manaswiyoungkul P., Olaoye O. O., Cabral A. D., Sedighi A., de Araujo E. D., Gunning P.T. ACS Med Chem Lett. 2020, 11:56-64. IF = 3.746.


99. High activation of STAT5A drives Peripheral T-Cell Lymphoma and Leukemia Maurer B., Nivarthi H., Wingelhofer B., Pham H. T. T., Grausenburger R., Schlederer M., Prchal-Murphy M., Chen D., Winkler S., Merkel O., Schiefer A-I., Kornauth C., Suske T., Hofbauer M., Hochgatterer B., Hoermann G., Hoelbl-Kovacic A., Cumaraswamy A. A., Eder G., Kitzwögerer M., Chott A., Pospíšilova S., Kubicek S., Valent P., Kolbe T., Grebien T., Kenner L., Gunning P. T., Kralovics R., Herling M., Müller M., Rülicke T., Sexl V., Moriggl  R. Haematologica 2020, 105, 435-447. IF = 7.57.

Let's Connect
  • LinkedIn - Black Circle
  • Twitter - Black Circle




  • White LinkedIn Icon
  • White Twitter Icon